At a glance
ClinicalIndex Comparison RecordN/ACompleted· 44 enrolled
Drug / intervention
Lactobacillus casei DG +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Lactobacillus Casei dg (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: Multicenter, Randomized, Double-blind, Cross-over, Placebo Controlled, Pilot Study
In Brief
A clinical study evaluating Lactobacillus casei DG and Placebo for Irritable Bowel Syndrome. Completed, enrolled 44 participants across 5 sites.
Detailed Summary
The aim of the study is to collect data for the assessment of the Lactobacillus casei DG (Enterolactis plus®) effect on overall abdominal pain/discomfort, symptoms and gut microbiota composition in patients with Irritable Bowel Syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedFeb 2015
Primary CompletionNov 2015
TodayJul 2026
First PostedFeb 25, 2015
Enrollment StartDec 1, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.4 years ago
Interventions
Lactobacillus casei DGdietary
the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
Placebodietary
the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks